TriSalus Life Sciences (NASDAQ:TLSI) Upgraded at Wall Street Zen

TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other research firms have also commented on TLSI. Zacks Research upgraded TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. Canaccord Genuity Group raised their price target on TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $11.00.

TriSalus Life Sciences Stock Down 0.4%

Shares of TriSalus Life Sciences stock opened at $4.97 on Friday. The stock has a market capitalization of $248.30 million, a price-to-earnings ratio of -2.46 and a beta of 0.43. TriSalus Life Sciences has a twelve month low of $3.42 and a twelve month high of $7.95. The company has a 50-day simple moving average of $6.37 and a two-hundred day simple moving average of $5.25.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.79). The business had revenue of $11.57 million for the quarter, compared to analysts’ expectations of $11.76 million. On average, sell-side analysts anticipate that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TriSalus Life Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. acquired a new position in TriSalus Life Sciences during the 1st quarter worth approximately $187,000. Geode Capital Management LLC grew its stake in shares of TriSalus Life Sciences by 107.4% during the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after buying an additional 235,627 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of TriSalus Life Sciences during the second quarter worth $29,000. JPMorgan Chase & Co. lifted its stake in shares of TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after acquiring an additional 7,519 shares during the last quarter. Finally, Connective Capital Management LLC boosted its holdings in shares of TriSalus Life Sciences by 12.8% during the 2nd quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock valued at $179,000 after acquiring an additional 3,717 shares in the last quarter. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.